Identifying treatment targets and biomarkers for dry eye disease in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the immunologic changes occurring in the ocular surface of cancer patients, particularly those with ocular graft-versus-host disease (oGVHD). It involves two groups: pre-bone marrow transplant cancer patients who will be assessed every three months for two years, and normal control patients evaluated every six months. During each visit, standard care exams will be conducted, and biological specimens will be collected for further analysis. The goal is to better understand the ocular surface conditions in these patients over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.
* The patient must be able to understand and sign and date the informed consent form approved by the IRB.

Exclusion Criteria:

* Vulnerable populations: neonates, children, prisoners, institutionalized individuals.
* Inability or refusal to provide informed consent.
* History of ocular surgery (except refractive surgery or cataract surgery)

Where it's running

• Geenebaum Cancer Center, University of Maryland Medical Center
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Sarah Sunshine, MD — University of Maryland, Baltimore
• Study coordinator: Sarah B Sunshine, MD
• Email: ssunshine@som.umaryland.edu
• Phone: 667-214-1292

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if TRYPTYR 0.003% helps dry eye symptoms and signs

  This study tests whether acoltremon 0.003% can improve symptoms and eye findings in adults with dry eye disease.

  Recruiting at 2 sites Scott & Christie and Associates, PC · Scottsdale, Arizona and 1 other locations · NCT07926594

• BL1107 dosing for drying eye redness: finding the lowest effective amount

  This trial tests whether different doses of BL1107 can fully reduce conjunctival redness in people with dry eye disease, while keeping participants unaware of the dose they receive.

  Recruiting Phase 2 Bausch & Lomb Incorporated · Newport Beach, California · NCT07778888

• d-MAPPS Ophthalmic Solution for adults with chronic oGVHD

  This Phase 3 trial tests whether d-MAPPS ophthalmic drops can help adults with chronic ocular graft-versus-host disease compared with a placebo-like vehicle over 90 days.

  Recruiting at 4 sites Phase 3 Regenerative Ocular Immunobiologics LLC · Beverly Hills, California and 4 other locations · NCT07776210

• Eye drops from umbilical cord stem cell vesicles to help dry eye

  A tiny drop of human umbilical cord stem cell–derived vesicles is applied to the eye daily for four weeks to see if it helps dry eye symptoms and signs.

  Recruiting Early Phase 1 The First Affiliated Hospital of Xiamen University · Xiamen, China · NCT07623382

• Tear iron levels and dry eye severity

  This project will see if the amount of iron in tears is linked to how severe someone's dry eye is by comparing people with dry eye to healthy volunteers.

  Recruiting Shanghai Changzheng Hospital · Shanghai · NCT07363824

• Vitamin A–based eye ointment for dry, burning, or irritated eyes

  This trial will try a vitamin A–based ointment called Vit-A-Vision in adults with dry eye symptoms to see if it improves comfort and tear stability.

  Recruiting OmniVision GmbH · Cologne · NCT06596733

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.